Evercore ISI Starts Organovo Holdings (ONVO) at Buy
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Evercore ISI initiates coverage on Organovo Holdings (NASDAQ: ONVO) with a Buy rating and a price target of $4.50.
Analyst Ross Muken commented, "Our BUY investment thesis rests on three key revenue growth drivers that will likely lead to Organovo being the ultimate winner in the nascent bioprinting market, and they include 1) rapid market adoption of 3D printed liver and kidney tissue used in preclinical toxicity studies, 2) pharma companies partnering / collaborating with ONVO for drug development screening within these tissues, and 3) the use of 3D printed liver tissue as a therapy for patients suffering severe liver disease."
Shares of Organovo Holdings closed at $3.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Downgrades PennTex Midstream Partners, LP (PTXP) to Hold
- Imperial Capital Raises Price Target on Eldorado Resorts (ERI) Ahead of Acquisition
- UPDATE: Stifel Upgrades Martin Midstream Partners (MMLP) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Hot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!